ID: ALA3289015

Max Phase: Preclinical

Molecular Formula: C21H19N5O3

Molecular Weight: 389.42

Molecule Type: Small molecule

Representations

Canonical SMILES:  N=C(N)c1ccc(Oc2cc(Oc3ccc(C(=N)N)cc3)cc(C(N)=O)c2)cc1

Standard InChI:  InChI=1S/C21H19N5O3/c22-19(23)12-1-5-15(6-2-12)28-17-9-14(21(26)27)10-18(11-17)29-16-7-3-13(4-8-16)20(24)25/h1-11H,(H3,22,23)(H3,24,25)(H2,26,27)

Standard InChI Key:  PXMXCALLMFUIOY-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 389.42

Molecular Weight (Monoisotopic): 389.1488

AlogP: 2.94

#Rotatable Bonds: 7

Polar Surface Area: 161.29

Molecular Species: BASE

HBA: 5

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 8

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 13.61

CX Basic pKa: 11.96

CX LogP: 1.76

CX LogD: -3.15

Aromatic Rings: 3

Heavy Atoms: 29

QED Weighted: 0.31

Np Likeness Score: -0.29

References

1. Goswami R, Mukherjee S, Ghadiyaram C, Wohlfahrt G, Sistla RK, Nagaraj J, Satyam LK, Subbarao K, Palakurthy RK, Gopinath S, Krishnamurthy NR, Ikonen T, Moilanen A, Subramanya HS, Kallio P, Ramachandra M..  (2014)  Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy.,  22  (12): [PMID:24794746] [10.1016/j.bmc.2014.04.013]

Source

Source(1):

• Scientific Literature